fasudil has been researched along with Blood Pressure, High in 28 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 7.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "These results suggest that fasudil has beneficial effects on retinal vascular complications associated with chronic hypertension." | 7.74 | Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. ( Ishii, K; Kametaka, S; Mori, A; Nakahara, T; Okamura, N; Saito, M; Sakamoto, K, 2007) |
| " A selective Rho-kinase inhibitor, fasudil, has recently been shown to improve renal damage resulting from hypertensive glomerulosclerosis, unilateral ureteral obstruction (for interstitial renal fibrosis) and subtotal nephrectomy." | 4.83 | Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. ( Hayashi, K; Homma, K; Kanda, T; Saruta, T; Sugano, N; Wakino, S, 2006) |
| "Twenty 12-week-old healthy male Sprague-Dawley rats were randomly divided into groups A (control), B (hypertension) and C (fasudil treatment)." | 3.78 | [Fasudil improves erectile function of hypertensive rats]. ( Chen, F; Cheng, Y; Jiang, R; Ma, ZP; Yang, HF, 2012) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 3.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "These results suggest that fasudil has beneficial effects on retinal vascular complications associated with chronic hypertension." | 3.74 | Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. ( Ishii, K; Kametaka, S; Mori, A; Nakahara, T; Okamura, N; Saito, M; Sakamoto, K, 2007) |
| "To determine the effects of fasudil, a Rho-kinase inhibitor, on mineralocorticoid-induced myocardial remodeling, we investigated whether fasudil would suppress myocardial fibrosis and inflammation in deoxycorticosterone-acetate (DOCA)/salt hypertensive rats." | 3.74 | Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. ( Inoue, H; Ishimaru, K; Kagitani, S; Takabayashi, D; Takata, M; Ueno, H, 2007) |
| "We investigated the effects of fasudil, a Rho kinase inhibitor, on hypertension in spontaneously hypertensive rats and on the catecholamine synthetic pathway." | 3.74 | Fasudil attenuates sympathetic nervous activity in the adrenal medulla of spontaneously hypertensive rats. ( Hayashi, M; Kobayashi, S; Kumai, T; Matsumoto, N; Nakaya, S; Takeba, Y; Tsuzuki, Y; Yanagida, Y, 2007) |
| "Fasudil treatment significantly ameliorated those DHF-related myocardial changes." | 1.35 | Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. ( Fukui, S; Fukumoto, Y; Kagaya, Y; Nawata, J; Saji, K; Shimokawa, H; Shinozaki, T; Suzuki, J; Tawara, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (60.71) | 29.6817 |
| 2010's | 11 (39.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, SL | 1 |
| Cipolla, MJ | 1 |
| Ocaranza, MP | 1 |
| Fierro, C | 1 |
| Jalil, JE | 1 |
| Moya, J | 1 |
| Gonzalez, L | 1 |
| Molina, C | 1 |
| Mancilla, C | 1 |
| Vaněčková, I | 2 |
| Behuliak, M | 2 |
| Hojná, S | 1 |
| Kopkan, L | 1 |
| Kadlecová, M | 1 |
| Zicha, J | 2 |
| Yuan, TY | 1 |
| Chen, D | 1 |
| Chen, YC | 1 |
| Zhang, HF | 1 |
| Niu, ZR | 1 |
| Jiao, XZ | 1 |
| Xie, P | 1 |
| Fang, LH | 1 |
| Du, GH | 1 |
| Snelder, N | 1 |
| Ploeger, BA | 1 |
| Luttringer, O | 1 |
| Rigel, DF | 1 |
| Fu, F | 1 |
| Beil, M | 1 |
| Stanski, DR | 1 |
| Danhof, M | 1 |
| Vavřínová, A | 1 |
| Bencze, M | 1 |
| Polgárová, K | 1 |
| Ergang, P | 1 |
| Kuneš, J | 1 |
| Chan, CK | 1 |
| Mak, JC | 1 |
| Man, RY | 1 |
| Vanhoutte, PM | 1 |
| Ying, Z | 1 |
| Yue, P | 1 |
| Xu, X | 1 |
| Zhong, M | 1 |
| Sun, Q | 1 |
| Mikolaj, M | 1 |
| Wang, A | 1 |
| Brook, RD | 1 |
| Chen, LC | 1 |
| Rajagopalan, S | 1 |
| Büssemaker, E | 1 |
| Herbrig, K | 1 |
| Pistrosch, F | 1 |
| Palm, C | 1 |
| Passauer, J | 1 |
| de Frutos, S | 1 |
| Caldwell, E | 1 |
| Nitta, CH | 1 |
| Kanagy, NL | 1 |
| Wang, J | 1 |
| Wang, W | 1 |
| Walker, MK | 1 |
| Gonzalez Bosc, LV | 1 |
| Ray, P | 1 |
| Wright, J | 1 |
| Adam, J | 1 |
| Boucharens, S | 1 |
| Black, D | 1 |
| Brown, AR | 1 |
| Epemolu, O | 1 |
| Fletcher, D | 1 |
| Huggett, M | 1 |
| Jones, P | 1 |
| Laats, S | 1 |
| Lyons, A | 1 |
| de Man, J | 1 |
| Morphy, R | 1 |
| Sherborne, B | 1 |
| Sherry, L | 1 |
| Straten, Nv | 1 |
| Westwood, P | 1 |
| York, M | 1 |
| Guo, P | 1 |
| Wu, C | 1 |
| Masaki, T | 1 |
| Mori, H | 1 |
| Nishiyama, A | 1 |
| Ma, ZP | 1 |
| Jiang, R | 1 |
| Cheng, Y | 1 |
| Yang, HF | 1 |
| Chen, F | 1 |
| Tsounapi, P | 1 |
| Saito, M | 2 |
| Kitatani, K | 1 |
| Dimitriadis, F | 1 |
| Ohmasa, F | 1 |
| Shimizu, S | 1 |
| Kinoshita, Y | 1 |
| Takenaka, A | 1 |
| Satoh, K | 1 |
| Mukai, Y | 1 |
| Kanda, T | 3 |
| Wakino, S | 3 |
| Hayashi, K | 3 |
| Homma, K | 3 |
| Ozawa, Y | 1 |
| Saruta, T | 3 |
| Nakayama, M | 1 |
| Amano, M | 1 |
| Kawabata, S | 1 |
| Kaibuchi, K | 1 |
| Takefuji, M | 1 |
| Jarajapu, YP | 1 |
| Knot, HJ | 1 |
| Yoshioka, K | 1 |
| Tatematsu, S | 1 |
| Hasegawa, K | 1 |
| Takamatsu, I | 1 |
| Sugano, N | 2 |
| Nishikimi, T | 2 |
| Matsuoka, H | 1 |
| Chapados, R | 1 |
| Abe, K | 1 |
| Ihida-Stansbury, K | 1 |
| McKean, D | 1 |
| Gates, AT | 1 |
| Kern, M | 1 |
| Merklinger, S | 1 |
| Elliott, J | 1 |
| Plant, A | 1 |
| Shimokawa, H | 3 |
| Jones, PL | 1 |
| Okamura, N | 1 |
| Mori, A | 1 |
| Sakamoto, K | 1 |
| Kametaka, S | 1 |
| Nakahara, T | 1 |
| Ishii, K | 1 |
| Ishimaru, K | 1 |
| Ueno, H | 1 |
| Kagitani, S | 1 |
| Takabayashi, D | 1 |
| Takata, M | 1 |
| Inoue, H | 1 |
| Kumai, T | 1 |
| Takeba, Y | 1 |
| Matsumoto, N | 1 |
| Nakaya, S | 1 |
| Tsuzuki, Y | 1 |
| Yanagida, Y | 1 |
| Hayashi, M | 1 |
| Kobayashi, S | 1 |
| Fukui, S | 1 |
| Fukumoto, Y | 1 |
| Suzuki, J | 1 |
| Saji, K | 1 |
| Nawata, J | 1 |
| Tawara, S | 1 |
| Shinozaki, T | 1 |
| Kagaya, Y | 1 |
| Masumoto, A | 1 |
| Hirooka, Y | 1 |
| Hironaga, K | 1 |
| Setoguchi, S | 1 |
| Takeshita, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Early Intracoronary Administration of Fasudil Hydrochloride on Myocardial Perfusion in the Primary PCI of ST-elevation Myocardial Infarction: an Prospective, Randomized and Multicenter Trial[NCT03753269] | Phase 4 | 600 participants (Anticipated) | Interventional | 2019-07-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for fasudil and Blood Pressure, High
| Article | Year |
|---|---|
[Involvement of small GTPase Rho and Rho-kinase in the pathogenesis of hypertension and hypertensive target organ damage].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Angina Pectoris; Animals; Arteriosclerosis; C | 2004 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Collagen; Disease Models, An | 2006 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Cyclin-Dependent Kinase Inhi | 2006 |
[Role of the Rho/Rho-kinase pathway in the development of hypertensive glomerulosclerosis: renoprotective effect of Rho-kinase inhibitor in hypertensive glomerulosclerosis and its molecular mechanism].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Glomerulosclerosis, | 2006 |
1 trial available for fasudil and Blood Pressure, High
| Article | Year |
|---|---|
Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Enzyme Inhibitors; Female; Forearm; Humans; Hypertens | 2001 |
23 other studies available for fasudil and Blood Pressure, High
| Article | Year |
|---|---|
Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebrovascular Circulation; Chronic Disease | 2017 |
Rho kinase activation in circulating leukocytes is related to hypertensive myocardial remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Atrial Remodeling; Blood Pressure; Cardiomeg | 2018 |
Exaggerated blood pressure response to fasudil or nifedipine in hypertensive Ren-2 transgenic rats: role of altered baroreflex.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Baroreflex; Blood Pressure; Calcium Channel | 2019 |
A novel hypertensive crisis rat model established by excessive norepinephrine infusion and the potential therapeutic effects of Rho-kinase inhibitors on it.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antihypertensive Agents; Blood Pressure; Hyp | 2019 |
Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amiloride; Amlodipine; Animals; Atropine; Enalapril; | 2014 |
Ontogenetic changes in contribution of calcium sensitization and calcium entry to blood pressure maintenance of Wistar-Kyoto and spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arteries; Blood Pressure; Calcium; Calcium C | 2015 |
Rho kinase inhibitors prevent endothelium-dependent contractions in the rat aorta.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Antihypertensive Agents; Aorta, Thor | 2009 |
Air pollution and cardiac remodeling: a role for RhoA/Rho-kinase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Atmosphere Exposure Chambers | 2009 |
Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Case-Control Studies; Dose-Response Relationship, Dru | 2009 |
NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Aorta, Thoracic; Bosentan; Dioxoles; | 2010 |
Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amines; Animals; Disease Models, Animal; Hypertension | 2011 |
Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Antihypertensive Agents; Biomar | 2011 |
[Fasudil improves erectile function of hypertensive rats].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Hypertension; Male; Penile Erection; Rats; R | 2012 |
Fasudil improves the endothelial dysfunction in the aorta of spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Aorta; Endothelium, Vascular; Gene Expressio | 2012 |
[Involvement of Rho-kinase in hypertensive vascular disease--a novel therapeutic target in hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Vessels; Cardiovascular Diseases; Hype | 2002 |
Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Cell Cycle Proteins; Cell Di | 2003 |
Relative contribution of Rho kinase and protein kinase C to myogenic tone in rat cerebral arteries in hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Amides; Animals; Benzophenanthridines; Blo | 2005 |
Rho-kinase as a molecular target for insulin resistance and hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Animals; Arterioles; Cell Line; Glucos | 2006 |
ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Blood Vessels; Cell Adhesion; Cell S | 2006 |
Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Blood Pressure; Dose-R | 2007 |
Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Cytokines; Desoxycorticoster | 2007 |
Fasudil attenuates sympathetic nervous activity in the adrenal medulla of spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenal Medulla; Animals; Blood Pressure; Blotting, W | 2007 |
Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Disease Models, Animal; D | 2008 |